EMBX Embrex

Embrex Names David Kelly Senior Director Product Management for Inovocox(TM) Coccidiosis Vaccine RESEARCH TRIANGLE PARK, N.C., Sept. 1 /PRNewswire-FirstCall/ -- David Kelly recently joined Embrex, Inc., (NASDAQ:EMBX), The In Ovo Company(R), as Senior Director Product Management, Inovocox(TM). Mr. Kelly is responsible for management of and planning for the introduction of the Inovocox(TM) in ovo (in the egg) coccidiosis vaccine upon approval from the U.S. Department of Agriculture. He reports to Brian Hrudka, Vice President of Global Marketing and Vice President of Latin America. Prior to joining Embrex, Mr. Kelly held the positions of Director of Poultry Marketing for the Americas and Worldwide, and Director of U.S. Poultry Sales for Schering Plough. In these positions he managed coccidiosis control products including vaccines based on traditional technology. "Embrex's innovative approach to treating coccidiosis intrigues me because of its ease of delivery and because it provides a new option to producers who may want to reduce their reliance on chemical compounds currently used to treat this harmful parasite," said Mr. Kelly. "My work will include further analysis of the global coccidiosis market with an initial focus on the United States, evaluation of the product's benefits to producers, and how to commercialize it upon approval from the USDA. I believe this product has a great deal of potential to benefit to the poultry industry." Added Mr. Hrudka: "David's knowledge of the coccidiosis market is second to none and his decision to join the Embrex team signals to all that Embrex has a product to watch in the coccidiosis arena. In his previous marketing and sales roles he became familiar with the needs of poultry producers in the United States and globally and he took the steps necessary to address those needs. He will apply these experiences and the knowledge gained towards an Inovocox(TM) product introduction in the United States, followed by launches in other countries around the world." Mr. Kelly holds a bachelor of science degree in Agricultural Resource Management from Arizona State University and a master's in international business administration from The American Graduate School of International Management (Thunderbird). He has extensive international poultry experience, having worked for leading companies such as Con Agra, Merial Select and Schering Plough in the United States and Latin America. Coccidiosis Coccidiosis is a parasitic disease of a bird's digestive system which interferes with the growth and nutritional uptake of a bird. Symptoms often include weight depression, intestinal lesions, diarrhea and occasional bloody feces. Most producers around the world currently control this disease by delivering prophylactic amounts of coccidiostats in the feed and water or by administering vaccines post-hatch. Embrex's Inovocox(TM) in ovo vaccine will be delivered to the chick embryo automatically through the company's Inovoject(R) automated egg injection system. It is made up of live Eimeria oocysts of four different strains that will be delivered via a single dose injection before hatch. Embrex estimates that approximately $350 million each year is spent on coccidiosis treatments worldwide. About Embrex Embrex, Inc., The In Ovo Company(R), headquartered in Research Triangle Park, NC, is an international agricultural biotechnology company engaged in the development of innovative in ovo (in the egg) solutions that meet the needs of today's global poultry industry. The company's unique integration of several scientific and engineering disciplines enables it to be the leading provider of in ovo, value-added solutions with its automated injection and detection devices as well as its select vaccines. For additional information, visit the company web site at http://www.embrex.com/ . These statements involve risks and uncertainties that could cause actual results to differ materially. Risks include without limitation the degree of growth in the poultry industry in the U.S. and globally, competition arising in the United States, possible decreases in production by our customers, avian disease outbreaks in Embrex's markets, market acceptance and cost of expansion in new geographic markets and with new products, including the Company's ability to penetrate new markets and the degree of market acceptance of new products, the complete commercial development of potential future products on a cost effective basis, including Gender Sort and Inovocox(TM), and the ability to obtain regulatory approval of products. Such approval is dependent upon a number of factors, such as results of trials, the discretion of regulatory officials, and potential changes in regulations. Additional information on these risks and other factors, which could affect the Company's financial results, is included in the Company's Forms 10-K, 10-Q and other filings with the Securities and Exchange Commission. Embrex(R), Bursaplex(R), Newplex(TM), Inovoject(R), Inovocox(TM), Egg Remover(R), Vaccine Saver(R), and The In Ovo Company(R) are trademarks of Embrex, Inc. CONTACT: Ellen T. Moore Vice President, Investor Relations & Corporate Communications (919) 314-2561 DATASOURCE: Embrex, Inc. CONTACT: Ellen T. Moore, Vice President, Investor Relations & Corporate Communications of Embrex, Inc., +1-919-314-2561 Web site: http://www.embrex.com/

Copyright